Table 1 Characteristics of the included studies
Study | Country | Trial number | Sample size | OA severity | Treatment process | Cell source | Mean age | Sex (M: F) | Intervention | Outcomes | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
Emadedin, 2018 [17] | Iran | NCT01504464 | BMMSC = 19; saline = 24 | KL of II, III, or IV; WOMAC > 25 | IA of 5 mL | Autologous | 53.4 | 27: 16 | 40 × 106 BMMSCs | VAS, WOMAC1~4, AE | 6 months |
Freitag, 2019 [18] | Australia | ACTRN12614000814673 | ADMSC = 10, CT = 10 | KL of II or III; NRS > 5 | IA of 3 mL | Autologous | 53.1 | 12: 8 | 100 × 106 ADMSCs | VAS, WOMAC1, AE | 12 months |
Gupta, 2016 [20] | India | NCT01453738 | BMMSC = 10; HA = 10 | KL of II or III | IA of 2 mL | Allogeneic | 56.5 | 3: 17 | 25 × 106 BMMSCs | VAS, WOMAC1~4, AE | 12 months |
Ha, 2018 [16] | China | – | UBMSC = 43; PRP = 44 | KL of I, II, or III | IA of 5 mL | Allogeneic | 56.3 | 26: 61 | 5 × 106 UBMSCs | VAS, AE | 12 months |
Khalifeh, 2019 [21] | Iran | IRCT2015101823298N | UBMSC = 10; saline = 10 | KL of II, III, or IV | IA of 10 mL | Allogeneic | 56.7 | 2: 18 | 50 × 106 UBMSCs | AE | 6 months |
Kuah, 2018 [22] | Australia | ACTRN12615000439549 | ADMSC = 8; saline = 4 | KL of I, II, or III; VAS > 35/100 | IA of 2 mL | Allogeneic | 52.2 | 5: 7 | 4 × 106 ADMSCs | VAS, WOMAC2, AE | 12 months |
Lamo-Espinosa, 2016 [24] | Spain | NCT02123368 | BMMSC = 10; HA = 10 | KL of II, III, or IV; VAS > 2.5/10 | IA of 4 mL | Autologous | 63.1 | 11: 9 | 10 × 106 BMMSCs | VAS, WOMAC1~4, AE | 12 months |
Lamo-Espinosa, 2020 [23] | Spain | NCT02365142 | BMMSC = 24; PRP = 26 | KL of II, III, or IV; VAS > 2.5/10 | IA of 8 mL | Autologous | 55.3 | 33: 17 | 100 × 106 BMMSCs | VAS, WOMAC1~4, AE | 12 months |
Lee, 2018 [25] | Korea | NCT02658344 | ADMSC = 12; saline = 12 | KL of II, III, or IV; VAS > 4/10 | IA of 3 mL | Autologous | 62.7 | 6: 18 | 100 × 106 ADMSCs | AE | 6 months |
Lu, 2019 [26] | China | NCT02162693 | ADMSC = 26, HA = 26 | KL of I, II, or III | IA of 2.5 mL | Autologous | 57.3 | 6: 46 | 50 × 106 ADMSCs | VAS, WOMAC1~4, AE | 12 months |
Lv, 2015 [27] | China | – | BMMSC = 40; HA = 40 | KL of I, II, or III | IA of 5 mL | Autologous | 55.5 | 27: 53 | 25 × 106 BMMSC | WOMAC1, AE | 12 months |
Matas, 2019 [28] | Chile | NCT02580695 | UBSMC = 9; HA = 8 | KL of I, II, or III | IA of 3 mL | Allogeneic | 55.5 | 6: 11 | 20 × 106 UBMSC | VAS, WOMAC1~4, AE | 12 months |
Mendoza, 2017 [19] | Mexico | NCT01485198 | BMMSC = 30; CT = 31 | KL of II or III | IA of 3 mL | Autologous | 57.5 | 16: 45 | 20 × 106 BMMSC | VAS, AE | 6 months |
Vangsness, 2014 [29] | America | NCT00225095 | BMMSC = 20; HA = 20 | PMM | IA of 5 mL | Allogeneic | 46.2 | 24: 16 | 20 × 106 BMMSC | AE | 24 months |
Vega, 2015 [30] | Spain | NCT01586312 | BMMSC = 15; HA = 15 | KL of II, III, or IV | IA of 3 mL | Allogeneic | 57 | 13: 17 | 40 × 106 BMMSC | VAS, WOMAC1~2, AE | 12 months |
Wang, 2016 [31] | China | – | UBMSC = 18; HA = 18 | KL of II, III, or IV | IA of 3 mL | Allogeneic | 53.5 | 21: 15 | 20 × 106 UBMSC | WOMAC1, AE | 6 months |